Market Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb Presents Promising Phase IIb Data for Novel, Investigational Attachment Inhibitor for HIV-1 Infected Treatment-Experienced Patients

[Business Wire] – Bristol-Myers Squibb Company today presented 24-week Phase IIb data that demonstrated similar response rates for its investigational compound, BMS-663068, when compared to a boosted protease inhibitor, Reyataz® with . . . → Read More: Market Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb Presents Promising Phase IIb Data for Novel, Investigational Attachment Inhibitor for HIV-1 Infected Treatment-Experienced Patients Similar Articles: Merck & Co. Inc. (NYSE:MRK) – 8:31 am Merck initiates rolling submission of U.S. Biologics License Application for MK-3475, an investigational Anti-PD-1 Immunotherapy, in patients with advanced melanoma; expects to complete application in 1H14 AbbVie Inc. (NYSE:ABBV) ~ AbbVie’s hepatitis C treatment helps 96 pct of patients in trial Stock market seasonality mid-year update